ArticleInfectious disease reports2019
Present and future of siderophore-based therapeutic and diagnostic approaches in infectious diseases.
Article in Infectious disease reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The structure of the full catalytic cycle ofbioRxiv : the preprint server for biology · 2025Article
- Biosynthesis of iron-chelating terramides A-C and their role in Aspergillus terreus infection.Communications chemistry · 2024Article
- Old and new strategies in therapy and diagnosis against fungal infections.Applied microbiology and biotechnology · 2024Review
- Opportunities and challenges of microbial siderophores in the medical field.Applied microbiology and biotechnology · 2023Review
- Engineering Siderophore Biosynthesis and Regulation Pathways to Increase Diversity and Availability.Biomolecules · 2023Review
- Siderophore conjugates to combat antibiotic-resistant bacteria.RSC medicinal chemistry · 2023Review
- Metals to combat antimicrobial resistance.Nature reviews. Chemistry · 2023Review
- A Four-Step Platform to Optimize Growth Conditions for High-Yield Production of Siderophores in Cyanobacteria.Metabolites · 2023Article
- Update on the Management of Surgical Site Infections.Antibiotics (Basel, Switzerland) · 2022Review
- Engineering siderophore production in Pseudomonas to improve asbestos weathering.Microbial biotechnology · 2022Article
- AntimicrobialAntibiotics (Basel, Switzerland) · 2022Review
- SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience.Frontiers in medicine · 2022Article
- Ins and Outs: Recent Advancements in Membrane Protein-Mediated Prokaryotic Ferrous Iron Transport.Biochemistry · 2021Review
- Structural and Biochemical Characterization of the Flavin-Dependent Siderophore-Interacting Protein fromACS omega · 2021Article
- New Perspectives on Antimicrobial Agents: Cefiderocol.Antimicrobial agents and chemotherapy · 2021Review
- Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.Journal of the American Chemical Society · 2020Article
- Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-ResistantOphthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron is an essential micronutrient required for the growth of almost all aerobic organisms; the iron uptake pathway in bacteria therefore represents a possible target for novel antimicrobials, including hybrids between antimicrobials and siderophores. Siderophores are low molecular weight iron chelators that bind to iron and are actively transported inside the cell through specific binding protein complexes. These binding protein complexes are present both in Gram negative bacteria, in their outer and inner membrane, and in Gram positive bacteria in their cytoplasmic membrane. Most bacteria have the ability to produce siderophores in order to survive in environments with limited concentrations of free iron, however some bacteria synthetize natural siderophore-antibiotic conjugates that exploit the siderophore-iron uptake pathway to deliver antibiotics into competing bacterial cells and gain a competitive advantage. This approach has been referred to as a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.